Initial trials in DLBCL have demonstrated modest activity [161,162,163], but a recent phase II study adding venetoclax to R-CHOP for previously untreated DLBCL has shown promising results, particularly in BCL2-positive cases [164]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.